Clovis ovarian cancer drug rucaparib dubbed 'breakthrough'

The FDA has granted breakthrough therapy status to Clovis Oncology investigational agent rucaparib as monotherapy to treat advanced ovarian cancer in patients who have received at least two lines of prior platinum-containing therapy, with BRCA-mutated tumors, inclusive of both germline BRCA (gBRCA) and somatic BRCA (sBRCA) mutations.